ストックスクリーナーアプリを入手
5.0101
1.19%
-0.0499
前日終値:
$5.06
開ける：
$4.91
24時間の取引高:
1.34M
Relative Volume:
1.12
時価総額：
$468.94M
収益：
$824.50M
当期純損益:
$-365.90M
株価収益率:
-1.2674
EPS:
-3.9531
ネットキャッシュフロー:
$-25.60M
1週間 パフォーマンス:
-2.53%
1か月 パフォーマンス:
+10.38%
6か月 パフォーマンス:
-30.94%
1年 パフォーマンス:
-51.97%
1日の値動き範囲:
$4.75
$5.105
1週間の範囲:
$4.75
$5.47
52週間の値動き範囲:
$3.76
$10.47
Myriad Genetics Inc Stock (MYGN) Company Profile
名前
Myriad Genetics Inc
セクター
電話
801-584-3600
住所
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Compare MYGN vs TMO, DHR, IDXX, A, WAT
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
5.015 | 473.15M | 824.50M | -365.90M | -25.60M | -3.9531 |
|
TMO
Thermo Fisher Scientific Inc
|
476.87 | 184.15B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
188.22 | 137.93B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
576.53 | 47.82B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
112.04 | 32.62B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
WAT
Waters Corp
|
287.56 | 29.19B | 3.17B | 642.63M | 516.49M | 10.77 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-21 | ダウングレード | Scotiabank | Sector Outperform → Sector Perform |
| 2025-05-08 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2025-05-07 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-04-09 | ダウングレード | Guggenheim | Buy → Neutral |
| 2025-03-12 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2025-02-12 | 開始されました | Craig Hallum | Buy |
| 2024-12-10 | 開始されました | UBS | Neutral |
| 2024-12-09 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-09-19 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-08-28 | 開始されました | Wells Fargo | Overweight |
| 2024-06-27 | 開始されました | Scotiabank | Sector Outperform |
| 2024-06-03 | 再開されました | Jefferies | Underperform |
| 2024-05-08 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2023-12-21 | 再開されました | Piper Sandler | Neutral |
| 2023-12-19 | 開始されました | Wells Fargo | Equal Weight |
| 2023-12-14 | 開始されました | Guggenheim | Buy |
| 2023-12-13 | 開始されました | Wolfe Research | Outperform |
| 2023-07-05 | 再開されました | JP Morgan | Underweight |
| 2023-05-23 | アップグレード | Goldman | Sell → Buy |
| 2023-01-18 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2022-10-06 | 開始されました | Stephens | Equal-Weight |
| 2021-10-15 | 再開されました | Cowen | Market Perform |
| 2021-06-15 | 開始されました | Raymond James | Mkt Perform |
| 2021-06-03 | 開始されました | Goldman | Sell |
| 2019-09-26 | ダウングレード | BofA/Merrill | Neutral → Underperform |
| 2019-08-14 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2019-08-02 | アップグレード | BofA/Merrill | Underperform → Neutral |
| 2019-08-01 | アップグレード | Barclays | Underweight → Equal Weight |
| 2019-07-29 | ダウングレード | Needham | Strong Buy → Hold |
| 2019-07-09 | ダウングレード | Cowen | Outperform → Market Perform |
| 2019-03-12 | 繰り返されました | Needham | Strong Buy |
| 2019-01-03 | 開始されました | Needham | Strong Buy |
| 2018-11-30 | アップグレード | Goldman | Sell → Neutral |
| 2018-10-10 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2018-07-11 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2018-03-21 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2018-01-29 | 開始されました | Goldman | Sell |
| 2018-01-22 | 繰り返されました | Barclays | Equal Weight |
| 2018-01-05 | 開始されました | BTIG Research | Buy |
| 2017-10-02 | 再開されました | Leerink Partners | Mkt Perform |
| 2017-08-09 | 繰り返されました | Barclays | Equal Weight |
| 2017-02-08 | アップグレード | Ladenburg Thalmann | Sell → Neutral |
| 2017-01-18 | 開始されました | Deutsche Bank | Sell |
| 2016-10-10 | ダウングレード | Ladenburg Thalmann | Neutral → Sell |
すべてを表示
Myriad Genetics Inc (MYGN) 最新ニュース
3 Reasons to Sell MYGN and 1 Stock to Buy Instead - Yahoo Finance
Stocks making big moves yesterday: nLIGHT, Myriad Genetics, Vertex Pharmaceuticals, Nextpower, and Teladoc - Yahoo Finance
Myriad Genetics at Leerink Conference: Strategic Moves in Cancer Care By Investing.com - Investing.com Canada
Myriad Genetics (MYGN) Shares Skyrocket, What You Need To Know - Finviz
Insider Buying: Samraat Raha Acquires 40,000 Shares of Myriad Ge - GuruFocus
Myriad Genetics (NASDAQ:MYGN) CEO Purchases $200,000.00 in Stock - MarketBeat
Raha, Myriad Genetics CEO, buys $199k in shares - Investing.com India
Trading Systems Reacting to (MYGN) Volatility - Stock Traders Daily
Trading Recap: Whats next for Myriad Genetics Inc stockBreakout Watch & Consistent Return Strategy Ideas - baoquankhu1.vn
Take Profit: What hedge funds are buying Myriad Genetics IncMarket Sentiment Review & Weekly High Momentum Picks - baoquankhu1.vn
Royce & Associates LP Makes New $4.84 Million Investment in Myriad Genetics, Inc. $MYGN - MarketBeat
Myriad Genetics Stock Up on New Breast Cancer MRD Test Launch | 2026News and Statistics - IndexBox
MYGN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Myriad Genetics (MYGN) Stock Trades Up, Here Is Why - Finviz
Myriad Commercially Launches Precise MRD with Select Community Oncologists - Bitget
Myriad Genetics (MYGN) CPO has shares withheld to cover taxes - Stock Titan
Myriad Genetics, Inc. (NASDAQ:MYGN) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Stock Rating Upgraded by Zacks Research - MarketBeat
MYGN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
PacBio, Myriad Genetics, LeMaitre, Hims & Hers Health, and GoodRx Shares Are Falling, What You Need To Know - Yahoo Finance
Myriad Genetics (NASDAQ:MYGN) Director S. Louise Phanstiel Buys 48,000 Shares - MarketBeat
Insider Buying: Myriad Genetics (NASDAQ:MYGN) Director Acquires 6,100 Shares of Stock - MarketBeat
S. Louise Phanstiel Acquires 50,407 Shares of Myriad Genetics (NASDAQ:MYGN) Stock - MarketBeat
Myriad Genetics Insider Bought Shares Worth $494,722, According to a Recent SEC Filing - marketscreener.com
Director Phanstiel adds 104,507 Myriad Genetics (MYGN) shares - Stock Titan
Myriad Genetics, Inc. (MYGN) Stock Analysis: Navigating a 60% Upside Potential Amidst Financial Challenges - DirectorsTalk Interviews
How Myriad Genetics Inc. (MYGN) Affects Rotational Strategy Timing - Stock Traders Daily
Piper Sandler Keeps Their Buy Rating on Myriad Genetics (MYGN) - The Globe and Mail
GXD-Bio Appeals Genetic Tester IP Loss Against Myriad - Law360
Myriad Genetics outlines $860M–$880M revenue target for 2026 while advancing cancer care continuum strategy - MSN
Myriad Genetics, Inc. (NASDAQ:MYGN) Q4 2025 Earnings Call Transcript - Insider Monkey
Myriad Genetics Inc files for mixed shelf of up to $200 millionSEC filing - marketscreener.com
Myriad Genetics Inc Files For Mixed Shelf Of Up To $200 MillionSEC Filing - TradingView
Myriad Genetics Q4 2025 slides: profitability improves, MRD launch ahead By Investing.com - Investing.com South Africa
Cancer, prenatal and mental health tests anchor Myriad (MYGN) 2025 plan - Stock Titan
MYGN: UBS Maintains Neutral Rating, Lowers Price Target to $6.00 - GuruFocus
MYGN: Wells Fargo Lowers Price Target for Myriad Genetics | MYGN Stock News - GuruFocus
Why Myriad Genetics (MYGN) Stock Is Trading Up Today - Finviz
Myriad Genetics (MYGN) Unveils New Data on Cancer Diagnostics at ASCO-GU 2026 - GuruFocus
UBS Adjusts Price Target on Myriad Genetics to $6 From $8, Maintains Neutral Rating - marketscreener.com
Wells Fargo & Company Cuts Myriad Genetics (NASDAQ:MYGN) Price Target to $6.00 - MarketBeat
Myriad Genetics Beats Q4 Expectations, Shares Surge Amid Core Franchise Growth - Seeking Alpha
Myriad Genetics Q4 2025 slides: profitability improves, MRD launch ahead - Investing.com Nigeria
Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad's Precise MRD, Prolaris, and MyRisk tests - Bitget
Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests - The Manila Times
Myriad cancer tests at ASCO-GU challenge prostate risk rules - Stock Titan
Myriad Genetics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
MYGN Stock Up on Q4 Earnings and Revenue Beat, Gross Margin Down - TradingView
Myriad Genetics (MYGN) Stock Surges on Earnings Beat and Revenue Goals - GuruFocus
Myriad Genetics jumps after Q4 beat; sees Q1 revenue rising 2%–4% Y/Y (MYGN:NASDAQ) - Seeking Alpha
Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution - The Manila Times
Myriad Genetics Inc (MYGN) 財務データ
収益
当期純利益
現金流量
EPS
0.87%
0.63%
大文字化:
|
ボリューム (24 時間):